Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

bioMérieux S.A.. (10/22/14). "Press Release: Business Review for the Nine Months Ended September 30, 2014". Marcy l’Étoile.

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 Advencis (FR)
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 molecular diagnostics
  Index term 2 Advencis–Mérieux: investment, 201410 acquisition of all shares of Advencis by bioMérieux
Persons Person Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)
  Person 2 Heilbronn, Laurence (Image Sept 201405 Partner + Consultant)

Solid growth in nine-month sales:
> Up 7.4%, including BioFire and at constant exchange rates
> Up 3.5% at constant exchange rates and scope of consolidation, in line with the full-year target

The Americas: a significant contribution to the Group's sales performance
> Up 7.1% at constant exchange rates and scope of consolidation

China: third-quarter acceleration in clinical application sales

2014 organic sales growth objective maintained

New platform acquired for industrial applications

"In the nine months ended September 30, 2014, bioMérieux's sales grew by 7.4% at constant exchange rates and by 3.5% at constant exchange rates and scope of consolidation," said Chief Executive Officer Alexandre Mérieux. "In line with our full-year target, our sales performance reflects our effectively balanced geographic positions and product portfolio. In addition, during the third quarter, we made further progress on the BioFire integration and launched innovative diagnostic solutions. Our solid growth momentum, combined with our Company's stronger fundamentals, allows us to confirm that we are maintaining our organic sales growth objective for 2014."

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2014.


In the first nine months of 2014, bioMérieux's revenue increased by 7.4% at constant exchange rates, including €45 million in sales from BioFire as from January 16, 2014. Organic growth (at constant exchange rates and scope of consolidation) came to 3.5%. Exchange rate fluctuations, primarily reflecting the rise in the euro against other currencies, resulted in a negative currency effect of €37 million, or 320 bps. In this environment, net sales for the period amounted to €1,193 million, up a reported 4.2% from €1,144 million in the first nine months of 2013.

[ ]

Record changed: 2016-01-10


Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

» top